natgillin/translations-raw huggingface dataset:
Additionally, aztreonam-treated patients had fewer hospitalisations due to respiratory events (40 versus 58, p = 0.044) and fewer respiratory events requiring the use of i.v. 
Dodatno je bilo v skupini bolnikov, zdravljenih z aztreonamom, manj hospitalizacij zaradi respiratornih dogodkov (40 v primerjavi z 58, p = 0,044) in manj respiratornih dogodkov, zaradi katerih je bila potrebna uporaba i.v.
But, if you cannot use the prepared dose straight away, replace the stopper in the vial and store in a refrigerator. 
Če pripravljenega odmerka ne morete takoj uporabiti, vialo ponovno zaprite z zamaškom in jo shranite v hladilnik.
Once treatment is complete, disconnect the Control Unit and take apart the Altera Nebuliser Handset for cleaning and disinfecting. 
Ko je zdravljenje zaključeno, izklopite kontrolno enoto in razstavite komplet z nebulatorjem Altera za čiščenje in dezinfekcijo.
Aztreonam for injection has not been formulated for inhalation, and contains arginine, a substance known to cause pulmonary inflammation. 
Aztreonam za injiciranje ni bil formuliran za inhaliranje in vsebuje arginin, snov, za katero je znano, da povzroča vnetje pljuč.
If for any reason you must stop the treatment before you have finished, press and hold the On/Off button for one full second. 
Če morate zaradi česarkoli zdravljenje prekiniti, preden ste končali, pritisnite in eno sekundo držite gumb za vklop/izklop.
Gently tap the vial against the side of the medicine reservoir if necessary. 
Z vialo nežno potrkajte na steno vsebnika za zdravilo, če je potrebno.
What if I need to stop my treatment before I've finished? 
Kaj moram narediti za predčasno ustavitev zdravljenja?
Plasma aztreonam concentrations in paediatric patients aged 3 months to < 6 years are comparable to those observed for children > 6 years, adolescents and adults. 
Koncentracije aztreonama v plazmi pri pediatričnih bolnikih, starih od 3 mesece do < 6 let, so primerljive s tistimi, ki so jih opazili pri otrocih, starih > 6 let, mladostnikih in odraslih.
There are no clinical data on the use of Cayston in pregnant women, therefore you should not take Cayston during pregnancy unless specifically discussed with your doctor. 
Kliničnih podatkov o uporabi zdravila Cayston pri nosečnicah ni, zato zdravila Cayston ne smete uporabljati, razen če ste se o tem natančno pogovorili s svojim zdravnikom.
There are no data on the use of Cayston in patients with severe hepatic impairment (ALT or AST greater than 5 times the upper limit of normal). 
Ni podatkov o uporabi zdravila Cayston pri bolnikih s hudo okvaro delovanja jeter (ALT ali AST več kot 5-kratna zgornja meja normale).
The following side effects have been observed after the use of aztreonam for injection, but not after taking Cayston: swelling of the face, lips, tongue and/or throat with difficulty in swallowing or breathing, sweating, skin irritation and flaking, itchy rash, flushing, small red spots and very rarely, blistering of the skin. 
Naslednje neželene učinke so opazili po uporabi aztreonama za injiciranje, vendar ne po uporabi zdravila Cayston: otekanje obraza, ustnic, jezika in/ali grla s težavami pri požiranju ali dihanju, potenje, draženje kože in luskavost, srbeč izpuščaj, rdečica, majhne rdeče pike in zelo redko mehurji na koži.
The 1 ml solvent is contained in a plastic ampoule. 
1 ml vehikla je v plastični ampuli.
Each of the three doses should be taken by inhalation at least four hours apart, using an Altera Nebuliser Handset. 
Vsakega od treh odmerkov je treba uporabiti z inhaliranjem z vsaj štiriurnim časovnim razmakom, z uporabo ustreznega kompleta z nebulatorjem Altera.
You may get a temporary lowering of lung function test result during treatment with Cayston, but this is typically not a lasting effect. 
Prehodno se vam med zdravljenjem z zdravilom Cayston lahko znižajo rezultati testa pljučne funkcije, vendar ta učinek običajno ni trajen.
Animal and human data demonstrate low risk of cross-reactivity between aztreonam and beta-lactam antibiotics. 
Podatki pri živalih in ljudeh kažejo majhno tveganje navzkrižne reakcije med aztreonamom in betalaktamskimi antibiotiki.
Genotoxicity (Chromosomal aberration and mouse lymphoma mutation assay) studies with aztreonam were negative. 
Študije genotoksičnosti (kromosomske aberacije in preskušanje mutacije mišjega limfoma) z aztreonamom so bile negativne.
There are rare reports of Class D beta-lactamases from clinical isolates of P. aeruginosa, OXA-11 (Turkey) and OXA-45 (United States) that hydrolyse aztreonam. 
Obstajajo redka poročila o betalaktamazah razreda D iz kliničnih izolatov P. aeruginosa, OXA-11 (Turčija) in OXA-45 (Združene države Amerike), ki hidrolizirajo aztreonam.
If you can't leave a gap of 4 hours just skip the missed dose. 
Če presledek med odmerki ne more biti 4-urni, preprosto izpustite pozabljeni odmerek.
The majority of the treatment-emergent isolations were intermittent. 
Večina izolacij, ki so se pojavile ob zdravljenju, je bila prehodnih.
bronchodilator mucolytics and lastly, Cayston. 
bronhodilatator mukolitiki in nazadnje zdravilo Cayston
Cayston can be used during breast-feeding. 
Zdravilo Cayston se lahko uporablja med dojenjem.
Cayston should not be used during pregnancy unless the clinical condition of the woman requires treatment with aztreonam. 
Zdravila Cayston ne smete uporabljati pri nosečnicah, razen če klinično stanje nosečnice zahteva zdravljenje z aztreonamom.
Short acting bronchodilators can be taken between 15 minutes and 4 hours and long acting bronchodilators can be taken between 30 minutes and 12 hours prior to each dose of Cayston. 
Kratkodelujoče bronhodilatatorje se lahko vzame med 15 minut in 4 ure, dolgodelujoče bronhodilatatorje pa med 30 minut in 12 ur pred vsakim odmerkom zdravila Cayston.
Clinical studies of Cayston did not include Cayston-treated patients aged 65 years and older to determine whether they respond differently from younger patients. 
V klinične študije z zdravilom Cayston ni bilo vključenih bolnikov, starih 65 let in starejših, zdravljenih z zdravilom Cayston, da bi se ugotovilo, ali je njihov odziv drugačen kot pri mlajših bolnikih.
During clinical studies of Cayston, isolation of MRSA did not result in worsening of lung function. 
V kliničnih študijah z zdravilom Cayston izolacija MRSA ni povzročila poslabšanja pljučne funkcije.
Fifty-nine paediatric patients aged 6 to 17 years were included in the study. 
V študijo je bilo vključenih 59 pediatričnih bolnikov, starih 6 do 17 let.
There are rare reports of organisms with metallo-beta-lactamases (MBLs), Class B, that are resistant to aztreonam, VIM-5 (K. pneumoniae and P. aeruginosa - Turkey), VIM-6 (P. putida - Singapore) and VIM-7 (P. aeruginosa - United States), however, it is possible that these organisms were expressing multiple resistance mechanisms and thus a MBL was not responsible for the observed resistance to aztreonam. 
Ni poročil o organizmih z metalo-betalaktamazami (MBL), razred B, ki so odporne na aztreonam, VIM-5 (K. pneumoniae in P. aeruginosa - Turčija), VIM-6 (P. putida - Singapur) in VIM-7 (P. aeruginosa - Združene države Amerike), vendar pa je možno, da so ti organizmi izražali multiple mehanizme odpornosti in zato MBL ni bil odgovoren na opazovano odpornost na aztreonam.
When treatment is complete, open the medicine cap to ensure that all medicine has been used. 
Po zaključenem zdravljenju odprite pokrov za zdravilo in se prepričajte, da je bilo vso zdravilo porabljeno.
You can breast-feed during treatment with Cayston because the amount of Cayston likely to be passed to your child during breast-feeding will be extremely small. 
Med zdravljenjem z zdravilom Cayston lahko dojite, saj je količina zdravila Cayston, ki med dojenjem prehaja na dojenega otroka, izjemno majhna.
The following rare and severe adverse reactions have been reported after parenteral use of other aztreonam containing products: toxic epidermal necrolysis, anaphylaxis, purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis. 
O naslednjih redkih in resnih neželenih učinkih so poročali po parenteralni uporabi drugih zdravil, ki vsebujejo aztreonam: toksična epidermalna nekroliza, anafilaksa, purpura, multiformni eritem, eksfoliativni dermatitis, urtikarija, petehije, pruritus, diaforeza.
As an inhaled medicine, Cayston could cause you to cough and this could lead to coughing up blood. 
Kot zdravilo za inhaliranje lahko zdravilo Cayston povzroči kašelj, kar lahko vodi do izkašljevanja krvi.
Do not use this medicine after the expiry date which is stated on the vial label, solvent ampoule and the carton. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na viali, ampuli z vehiklom in škatli.
The information that appears on the solvent ampoule is provided in English only (see section 6). 
Informacije na ampuli z vehiklom so samo v angleščini (glejte poglavje 6).
Cystic fibrosis, also known as mucoviscidosis, is a life-threatening inherited disease that affects the mucus glands of internal organs, especially the lungs, but also of the liver, pancreas, and the digestive system. 
Cistična fibroza, znana tudi kot mukoviscidoza, je življenjsko nevarna dedna bolezen, ki prizadene žleze sluznice notranjih organov, zlasti pljuč, pa tudi jeter, trebušne slinavke in prebavnega sistema.
Data from these studies revealed minimal differences in mean plasma aztreonam concentrations between age groups in patients receiving Cayston 3 times a day. 
Podatki iz teh študij so razkrili minimalno razliko v srednji koncentraciji aztreonama v plazmi med starostnimi skupinami bolnikov, ki so prejemali zdravilo Cayston 3-krat dnevno.
- Do not use Cayston if it has been stored outside a refrigerator for more than 28 days. 
- Ne uporabljajte zdravila Cayston, če je bilo shranjeno zunaj hladilnika več kot 28 dni.
Adverse reactions specifically associated with overdose of Cayston have not been identified. 
Neželenih učinkov, povezanih s prevelikim odmerjanjem zdravila Cayston, niso opredelili.
Contents of the pack and other information What Cayston and the solvent contain 
Vsebina pakiranja in dodatne informacije Kaj vsebujeta zdravilo Cayston in vehikel
Bronchospasm (an acute reduction of ≥ 15% in FEV1) is a complication associated with nebulised therapies. 
Bronhospazem (akutno zmanjšanje ≥ 15 % FEV1) je zaplet, povezan z zdravljenjem z nebulatorjem.
Following administration of aztreonam for injection, aztreonam is excreted in human milk at very low concentrations. 
Po uporabi aztreonama za injiciranje se aztreonam izloča v materino mleko v zelo nizkih koncentracijah.
If aerosol mist does not begin to flow, please refer to the Altera manual for information. 
Če aerosol ne začne pršeti, preberite priročnik Altera za več informacij.
If you have taken more Cayston than you should, talk to a doctor or pharmacist immediately. 
Če ste uporabili večji odmerek zdravila Cayston kot bi smeli, se takoj posvetujte z zdravnikom ali farmacevtom.
Cayston was compared to TNS over three 28-day courses of treatment in a randomised, activecontrolled, multicenter study (GS-US-205-0110). 
Zdravilo Cayston so primerjali z RTN v treh 28-dnevnih ciklih zdravljenja v randomizirani, aktivno kontrolirani multricentrični študiji (GS-US-205-0110).
The Kaplan-Meier estimates for this event rate at week 24 were 36% in aztreonamtreated patients and 54% in TNS-treated patients. 
Ocena po metodi Kaplan-Meier za ta delež dogodkov v 24. tednu je bila 36 % v skupini, zdravljeni z aztreonamom, in 54 % v skupini, zdravljeni z RTN.
Patients received Cayston at the same frequency (2 or 3 times a day) as they took Cayston or placebo in the randomised studies. 
Bolniki so prejemali zdravilo Cayston enako pogosto (2-krat ali 3-krat na dan) kot so prejemali zdravilo Cayston ali placebo v randomiziranih študijah.
- Each dose consists of one vial of Cayston mixed with one ampoule of solvent. 
- Vsak odmerek je sestavljen iz ene viale zdravila Cayston, zmešane z eno ampulo vehikla.
Check that your nebuliser works properly before starting your treatment with Cayston. 
Preverite, ali nebulator pravilno deluje, preden uporabite zdravilo Cayston.
Inhalation of nebulised solutions may induce a cough reflex which could aggravate underlying conditions (see section 4.4). 
Inhaliranje nebuliziranih raztopin lahko povzroči refleks kašlja, ki osnovno bolezen poslabša (glejte poglavje 4.4).
Resistance to aztreonam, other antibiotics and treatment-emergent microorganisms 
Odpornost na aztreonam, druge antibiotike in mikroorganizme, ki se pojavijo med zdravljenjem
The European Medicines Agency has deferred the obligation to submit the results of studies with Cayston in one or more subsets of the paediatric population in cystic fibrosis patients with Pseudomonas aeruginosa pulmonary infection/colonisation (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Cayston za eno ali več podskupin pediatrične populacije bolnikov s cistično fibrozo z okužbo/kolonizacijo z bakterijo Pseudomonas aeruginosa (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Cayston was evaluated over a period of 28-days of treatment (one course) in two randomised, doubleblind, placebo-controlled, multicentre studies (CP-AI-005 and CP-AI-007). 
Zdravilo Cayston so ocenili v 28 dneh zdravljenja (en cikel zdravljenja) v dveh randomiziranih, dvojno-slepih, s placebom kontroliranih, multicentričnih študijah (CP-AI-005 in CP-AI-007).
This pack contains one Altera Nebuliser Handset. 
Ta paket vsebuje en komplet z nebulatorjem Altera.
For complete details on cleaning and disinfecting refer to the manufacturer's instructions for use provided with your Altera Nebuliser Handset. 
Za vse podrobnosti o čiščenju in razkužitvi preberite proizvajalčeva navodila, ki ste jih prejeli s kompletom z nebulatorjem Altera.
An Altera Nebuliser Handset containing an Altera Aerosol Head connected to an eFlow Control Unit of the type 178 (eFlow rapid) or type 678 (eBase Controller). 
komplet z nebulatorjem Altera, ki vsebuje glavo za izdelavo aerosola Altera, povezan s kontrolno enoto eFlow vrste 178 (eFlow rapid) ali vrste 678 (kontrolnik eBase).
Do not try to take Cayston using any other type of nebuliser handset (including the eFlow rapid handset). 
Zdravila Cayston ne uporabljajte z nobeno drugo vrsto kompleta z nebulatorjem (vključno s kompletom eFlow rapid).
Step D: When the metal seal opens, continue to slowly pull on the blue cap in a counterclockwise direction until the metal seal is completely removed. 
Korak D: Ko se kovinsko tesnilo odpre, še naprej počasi vlecite modro zaporko v obratni smeri urnega kazalca, dokler kovinskega tesnila povsem ne odstranite.
Cystic fibrosis in the lungs leads to clogging them with thick sticky mucus. 
Cistična fibroza v pljučih povzroči njihovo zamašitev z lepljivo sluzjo.
Patients participating in these studies could subsequently receive multiple courses of Cayston in an open-label follow-on study (CP-AI-006). 
Bolniki, ki so sodelovali v teh študijah, so lahko nato prejeli več ciklov zdravljenja z zdravilom Cayston v odprti nadaljevalni študiji (CP-AI-006).
injection in rats at daily doses up to 750 mg/kg without adverse effects. 
perinatalnega in postnatalnega za razvoja pri dnevnih odmerkih do 750 mg/kg brez neželenih učinkov.
Patients treated with aztreonamexperienced a longer time to need for i.v. 
Bolniki, zdravljeni z aztreonamom, dalj časa niso potrebovali i.v.
The serum half-life of aztreonam averaged 1.7 hours in subjects with normal renal function, independent of the dose and route. 
Razpolovni čas aztreonama v serum je bil povprečno 1,7 ure pri osebah z normalnim delovanjem ledvic, ne glede na odmerek in pot uporabe.
If there is more than a few drops of liquid left, replace the medicine cap and restart treatment. 
Če vidite več kot nekaj kapljic tekočine, ponovno namestite pokrov za zdravilo in nadaljujte z zdravljenjem.
Patients participating in this study in Europe who completed at least 1 course of Cayston or TNS during the randomised phase could subsequently receive up to three 28-day courses of Cayston in an open-label extension phase. 
Bolniki, ki so sodelovali v tej študiji v Evropi in so zaključili vsaj 1 cikel zdravljenja z zdravilom Cayston ali RTN med randomizirano fazo, so lahko nato prejeli do tri 28-dnevne cikle zdravljenja z zdravilom Cayston v odprti podaljšani fazi.
If you take more Cayston than you should 
Če ste uporabili večji odmerek zdravila Cayston, kot bi smeli
Cross-reactivity may occur in patients with a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems. 
Navzkrižne reakcije se lahko pojavijo pri bolnikih z anamnezo alergij na betalaktamske antibiotike kot so penicilini, cefalosporini in/ali karbapenemi.
Nebulised therapies, including Cayston, may be associated with bronchospasm (an acute reduction of ≥ 15% in FEV1). 
Zdravljenje z nebulatorjem, vključno z zdravilom Cayston, je lahko povezano z bronhospazmom (akutno zmanjšanje FEV1 ≥ 15%).
Assessment of adverse reactions is based on experience in four Phase 3 clinical studies involving CF patients with chronic P. aeruginosa infection and post-marketing spontaneous reporting. 
Ocena neželenih učinkov temelji na izkušnjah v štirih kliničnih študijah faze 3, v katere so bili vključeni bolniki s CF s kronično okužbo z bakterijo P. aeruginosa, in na spontanih poročilih iz obdobja trženja.
Approximately 10% of the total inhaled aztreonamdose is excreted in the urine as unchanged drug, as compared to 60-65% following intravenous administration of aztreonam for injection. 
Približno 10% celokupnega odmerka inhaliranega aztreonama se izloči v urinu v obliki nespremenjenega zdravila, v primerjavi s 60-65% po intravenskem dajanju aztreonama za injiciranje.
Make sure the Altera Nebuliser Handset is on a flat, stable surface. 
Komplet z nebulatorjem Altera zagotovo postavite na ravno, stabilno površino.
Bronchospasm has been reported after Cayston administration (see section 4.8). 
O bronhospazmu so poročali po dajanju zdravila Cayston (glejte poglavje 4.8).
Intravenous aztreonam is not suitable for inhalation. 
Aztreonam za intravensko uporabo ni primeren za inhaliranje.
Pharmacokinetic studies have not been performed in patients with renal or hepatic impairment. 
Farmakokinetičnih študij pri bolnikih z okvarjenim delovanjem ledvic ali jeter niso opravili.
Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, including P. aeruginosa. 
Aztreonam kaže in vitro aktivnost proti gram-negativnim aerobnim povzročiteljem bolezni, vključno s P. aeruginosa.
Lung function test decreased has been reported with use of Cayston, but was not associated with a sustained decrease in FEV1 (see section 5.1). 
Pri uporabi zdravila Cayston so poročali o poslabšanju testa pljučne funkcije, vendar ni bilo povezano s trajnim zmanjšanjem FEV1 (glejte poglavje 5.1).
- Do not use the solvent or prepared Cayston if it is cloudy or if there are particles in the solution. 
- Ne uporabljajte vehikla ali pripravljenega zdravila Cayston, če je motno ali če v raztopini opazite delce.
For storage conditions of the reconstitued medicinal product, see section 6.3. 
Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
Cayston is not expected to affect your ability to drive or use machines. 
Ne pričakuje se, da bi zdravilo Cayston vplivalo na sposobnost vožnje ali upravljanja strojev.
To re-start the treatment, press and hold the On/Off button for one full second and then restart the treatment. 
Za ponovni začetek zdravljenja pritisnite gumb za vklop/izklop in ga držite eno sekundo, nato pa nadaljujte z zdravljenjem.
In GS-US-205-0110, 268 patients with CF and chronic P. aeruginosa lung infection were randomised and received Cayston (n = 136) or TNS (n = 132). 
V študiji GS-US-205-0110 je bilo randomiziranih 268 bolnikov s CF in kronično pljučno okužbo s P. aeruginosa, ki so prejemali zdravilo Cayston (n = 136) ali TNS (n = 132).
Loss of susceptibility to aztreonam in CF patients with P. aeruginosa occurs either through selection of strains with mutations located on the chromosome or rarely through acquisition of plasmid/integron mediated genes. 
Do izgube občutljivosti na aztreonam pri bolnikih s CF, okuženih s P. aeruginosa, pride bodisi z izbiro sevov z mutacijami na kromosomu, ali redko s pridobivanjem genov prek plazmidov/integronov.
Following reconstitution, Cayston is a clear, colourless to slightly coloured solution. 
Po rekonstituciji je zdravilo Cayston bistra, brezbarvna do rahlo obarvana raztopina.
Therefore, and because of low oral absorption, aztreonam exposure in breast-fed infants due to mothers receiving Cayston is likely to be extremely low. 
Zaradi tega in zaradi nizke peroralne absorpcije je verjetnost izpostavljenosti dojenih otrok aztreonamu pri materah, ki uporabljajo zdravilo Cayston, izjemno majhna.
Be sure to completely empty the vial. 
Povsem izpraznite vialo.
In studies of up to nine 28-day courses of Cayston therapy, no increases of clinical significance were observed in the treatment-emergent isolation of other gram-negative bacterial respiratory pathogens (Burkholderia species, Stenotrophomonas maltophilia and Alcaligenes species). 
V študijah do devetih 28-dnevnih ciklov zdravljenja z zdravilom Cayston niso opazili povečanja klinične pomembnosti v izolaciji drugih gramnegativnih bakterijskih respiratornih povzročiteljev, ki so se pojavili v povezavi z zdravljenjem (vrste Burkholderia, Stenotrophomonas maltophilia in vrste Alcaligenes).
Aztreonam for injection must not be used in the Altera or other nebulisers. 
Aztreonam za injiciranje se ne sme uporabljati v nebulatorju Altera ali drugih nebulatorjih.
An acute reduction of ≥ 15% in FEV1 is a complication associated with nebulised therapies, including Cayston (see section 4.4). 
Akutno zmanjšanje FEV1 ≥ 15% je zaplet, povezan z zdravljenjem z nebulatorjem, ki vključuje tudi zdravilo Cayston (glejte poglavje 4.4).
A few drops of medicine may remain in the reservoir at the end of treatment. 
V vsebniku za zdravilo sme po koncu zdravljenja ostati nekaj kapljic zdravila.
Cayston should not be used with any other type of handset or aerosol head. 
Cayston se ne sme uporabljati z nobeno drugo vrsto kompleta ali glavo za izdelavo aerosola.
If Cayston is to be prescribed to the elderly then the posology is the same as for adults. 
Če se zdravilo Cayston predpiše starejšim bolnikom je odmerjanje enako kot pri odraslih.
Cayston has no or negligible influence on the ability to drive or use machines. 
Zdravilo Cayston nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Powder vial and solvent ampoule: Store in a refrigerator (2°C - 8°C). 
Viala s praškom in ampula z vehiklom: Shranjujte v hladilniku (2 °C - 8 °C).
Patients continued on their baseline medications and whenever indicated additional antibiotics were used in the majority of patients to treat exacerbations. 
Kadar je bilo indicirano, so pri večini bolnikov uporabili dodatne antibiotike za zdravljenje eksacerbacij.
A single sputum sample from a CF patient may contain multiple isolates of P. aeruginosa and each isolate may have a different level of in vitro susceptibility to aztreonam. 
En sam vzorec izpljunka bolnika s CF lahko vsebuje več izolatov povzročitelja P. aeruginosa in vsak posamezni izolat lahko izkazuje različno raven in vitro občutljivosti na aztreonam.
One hour following a single dose of 75 mg inhaled aztreonam (at approximately peak plasma concentration), the mean plasma level in patients with CF was 0.59 µg/ml. 
Eno uro po enem 75-mg odmerku inhaliranega aztreonama (približno pri najvišji koncentraciji v plazmi) je bila srednja raven v plazmi pri bolnikih s CF 0,59 µg/ml.
Step C: While continuing to hold the vial steady with one hand, use the other hand to slowly pull the blue cap in a counterclockwise direction. 
Korak C: Medtem ko z eno roko še vedno trdno držite vialo, z drugo roko počasi vlecite modro zaporko v obratni smeri urnega kazalca.